Malaria is no longer a disease held back by a lack of solutions. The real problem now lies in delivery—weak systems, uneven access, and heavy dependence on external supply chains that often fail when they are needed most.
As World Malaria Day 2026 is observed under the theme “Now We Can. Now We Must,” the global focus is shifting sharply. The question is no longer whether malaria can be treated, but whether proven interventions can reliably reach those who need them.
Nowhere is that challenge more urgent than in Nigeria, which remains the global epicentre of malaria. The World Health Organization estimates that the country accounts for about 27% of global cases and nearly one in every three malaria-related deaths. Behind those figures are overcrowded hospitals, missed education, lost income, and thousands of preventable deaths—especially among children under five and pregnant women.
Against this reality, Emzor Pharmaceutical Industries Limited is pushing a different approach to malaria elimination. The company argues that treatment alone is not enough, and that Nigeria must build a stronger pharmaceutical base capable of sustaining access to essential medicines at scale.
At the centre of its argument is local manufacturing. For years, Nigeria’s heavy reliance on imported drugs has exposed its health system to global supply disruptions, currency instability, and shifting international priorities. When those pressures hit, access to essential medicines becomes uncertain—even in moments of urgent need.
Emzor’s Executive Director, Uzoma Ezeoke, says domestic production is now a matter of national security rather than industrial preference.
“Local manufacturing is no longer optional—it is central to our national health security,” she said.
The company also draws attention to a deeper structural weakness: Nigeria’s dependence on imported Active Pharmaceutical Ingredients (APIs), the core chemical components used in drug production. While medicines may be packaged locally, the most critical inputs still come from abroad.
Emzor Chairman Emeka Okoli warns that this creates a hidden vulnerability in the healthcare system. Without local API production, the entire pharmaceutical value chain remains exposed to external shocks, limiting both resilience and long-term affordability.
Building that capacity locally, he argues, would do more than secure supply chains. It would strengthen regulatory oversight, improve quality control, and position Nigeria for broader industrial growth in the health sector.
More importantly, it would shift the country from dependency to capability—allowing Nigeria not just to respond to malaria, but to prepare for future public health challenges with greater independence.
Still, the success of any manufacturing strategy ultimately depends on what happens at patient level. In malaria treatment, access alone is not enough; usability matters just as much.
Children, in particular, often struggle with standard tablet-based medication, leading to missed doses and reduced treatment effectiveness. To address this, Emzor developed Lokmal Dispersible Tablets, designed for children aged three months to five years. The tablets dissolve easily in water or milk, making administration simpler for caregivers and improving adherence to treatment.
For pregnant women, the company promotes Maldox, used in intermittent preventive treatment during pregnancy (IPTp). The goal is to reduce infection risk at a critical stage, protecting both mother and child before complications arise.
These innovations reflect a broader shift in thinking—towards designing healthcare solutions that match real-life conditions, not just clinical expectations. Accessibility, in this sense, is about practicality, ease of use, and consistency in everyday environments.
Despite these efforts, stakeholders agree that no single organisation can eliminate malaria alone. Nigeria’s scale demands coordinated action across government, private sector, and international partners.
Emzor stresses that policy support is essential to drive local manufacturing, while development partners must prioritise long-term system building rather than short-term interventions. Private investors, meanwhile, are expected to back both production and innovation.
Okoli summarised the urgency clearly: “The time to move from commitment to execution is now.”
The implications go far beyond health. A stronger pharmaceutical sector would create jobs, stimulate economic growth, and position Nigeria as a regional hub for medicine production. Failure to act, however, risks locking the country into continued dependency, where progress is shaped by forces beyond its control.
There is growing recognition that the tools to end malaria already exist. What remains missing is not science, but system strength—the ability to deliver consistently, at scale, and without interruption.
As World Malaria Day 2026 is marked, Nigeria’s message is becoming clearer: ending malaria is possible, but only if the country builds systems that make success permanent, not temporary.
Because in the end, the real divide is no longer between treatment and cure—it is between managing malaria and finally ending it.
